Abstract:
Objective To investigate the prognostic value of pretreatment peripheral blood inflammatory markers in epidermal growth factor receptor (EGFR)-mutant advanced non-small cell lung cancer (NSCLC).
Methods We retrospectively analyzed clinical data of 142 patients with EGFR-mutant advanced NSCLC treated at The Fifth Medical Center, Chinese PLA General Hospital, from January 2015 to October 2018. Receiver operating characteristic (ROC) curve analysis was employed to determine optimal cutoff values of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII), and lymphocyte-to-monocyte ratio (LMR) for predicting survival. The Kaplan-Meier method was used for survival analysis. A Cox proportional risk model was used to evaluate the predictive value of each variable.
Results The optimal cutoff values of NLR, PLR, SII, and LMR were 2.60, 167.32, 687.39, and 3.13, respectively. Patients were assigned into high and low NLR, PLR, SII, and LMR groups according to the optimal cutoff values. The median progression-free survival (mPFS) and overall survival (mOS) of the high NLR, PLR, and SII groups were significantly shorter than those of the low NLR, PLR, and SII groups, respectively. The mPFS and mOS of the high LMR group were longer than those of the low LMR group.
Conclusions High NLR, PLR, and SII and low LMR before treatment may be associated with poor prognosis of patients with EGFR-mutant advanced NSCLC who receive targeted therapy.